openPR Logo
Press release

Nyxol (Phentolamine Mesylate) by Ocuphire Pharma expected to drive market size of Glaucoma

03-11-2024 11:59 AM CET | Health & Medicine

Press release from: DelveInsight Business Research

Nyxol (Phentolamine Mesylate) by Ocuphire Pharma expected

[Las Vegas, United States] DelveInsight, a leader in healthcare research firm, has recently published an in-depth report on Nyxol (Phentolamine Mesylate) (Ocuphire Pharma) providing insights into the drug market landscape and market forecast of Nyxol (Phentolamine Mesylate) upto 2032. The report, titled "Nyxol (Phentolamine Mesylate) Market Size, Forecast, and Emerging Insight - 2032" is now available for review and analysis.
Are you interested in finding out the projected market size of Nyxol (Phentolamine Mesylate) in 2032? Nyxol (Phentolamine Mesylate) Market Forecast https://www.delveinsight.com/report-store/nyxol-phentolamine-mesylate-emerging-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
The Nyxol (Phentolamine Mesylate) Market Report offers projected sales forecasts for Nyxol (Phentolamine Mesylate) for indications until 2032, categorized across the 7MM i.e. United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report also provides extensive coverage and a competitive landscape analysis of competitors and marketed products indication. It also covers analyst views along with market drivers and barriers.
Ocuphire Pharma's Nyxol (Phentolamine Mesylate) is serving as a beacon of hope for the patients suffering from the Glaucoma.
What is a Nyxol (Phentolamine Mesylate) Prescribed for?
Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company specializing in ophthalmic therapies for refractive and retinal eye disorders, has received acceptance from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for Nyxol® (phentolamine ophthalmic solution 0.75%). The application pertains to the treatment of pharmacologically-induced mydriasis (RM).

The report extensively covers the details and developments related to Nyxol (Phentolamine Mesylate), capturing important highlights on developmental pipeline, regulatory status and special designations of Nyxol (Phentolamine Mesylate), route of administration, safety and efficacy details.

Nyxol (Phentolamine Mesylate) Market Assessment
This report provides a detailed market assessment of Nyxol (Phentolamine Mesylate) for Glaucoma in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2028 to 2032.

Nyxol (Phentolamine Mesylate) Clinical Assessment
The report provides the clinical trials information of Nyxol (Phentolamine Mesylate) for Glaucoma covering trial interventions, trial conditions, trial status, start and completion dates. Report also includes important insights on regulatory milestones and other developmental activities related.
Do you know your drug's competitive positioning against Nyxol (Phentolamine Mesylate)? Nyxol (Phentolamine Mesylate) Drugs Insights
https://www.delveinsight.com/report-store/nyxol-phentolamine-mesylate-emerging-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Nyxol (Phentolamine Mesylate) Competitive Landscape
The report offers insights into the key players and companies actively engaged in the development of the specified indication. It provides valuable information regarding the competitive positioning of the Nyxol (Phentolamine Mesylate).

Nyxol (Phentolamine Mesylate) Market Size in the US
A dedicated section of the report focuses on the expected market size of Nyxol (Phentolamine Mesylate) for the United States. DelveInsight's analysis includes market trends, growth projections, and key factors influencing the market dynamics, offering a comprehensive perspective for stakeholders.

Key Highlights of Nyxol (Phentolamine Mesylate):

• The report contains forecasted sales of Nyxol (Phentolamine Mesylate) for indication till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Glaucoma.
• The report also features the qualitative and quantitative analysis with analysts as well as KOL views for Nyxol (Phentolamine Mesylate) in Glaucoma.
Stay ahead in competition by leveraging insights on Nyxol (Phentolamine Mesylate) market Report: Download Nyxol (Phentolamine Mesylate) Market Report
https://www.delveinsight.com/sample-request/nyxol-phentolamine-mesylate-emerging-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Why you should buy Nyxol (Phentolamine Mesylate) Market Report:
• The report provides future market assessments for Nyxol (Phentolamine Mesylate) for Glaucoma in the 7 Major Markets, Advance qualitative analysis like SWOT, expert analysts' views, detailed overview of market competitors, and short analysis of other emerging therapies in Ulcerative Colitis.
• Leading Nyxol (Phentolamine Mesylate) for Glaucoma forecasted market data will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Nyxol (Phentolamine Mesylate)
• Discover the competitive landscape of Nyxol (Phentolamine Mesylate) through 7MM
• Get a Thorough Analysis of the Nyxol (Phentolamine Mesylate) Development pipeline, Safety & Efficacy of the Nyxol (Phentolamine Mesylate), and ROA
• Thorough Nyxol (Phentolamine Mesylate) market forecast will help understand how drug is competing with other emerging Nyxol (Phentolamine Mesylate)
• Get analysis of the Nyxol (Phentolamine Mesylate) clinical trial advancements and the detailed clinical assessment, regulatory and commercial assessment
• Drug Market forecasts are calculated after taking into consideration KOL viewpoints

Related Reports By DelveInsight:

Glaucoma Pipeline https://www.delveinsight.com/report-store/glaucoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's, "Glaucoma Pipeline Insight, 2024" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Glaucoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. The key Glaucoma companies developing therapies include - Santen Pharmaceuticals, Visiox Pharma, Nicox Ophthalmics, pH Pharma, Omikron Italia, Tarsier Pharma, Tear Clear, Laboratoires Thea, EMS, Peregrine Ophthalmic, Betaliq, Inc., Ocuphire Pharma,Inc., HKinno.N, VivaVision Biotech, QlarisBio, and others.
It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Top Services Offered By DelveInsight:

Elevate your business with our Market Assessment case study. Transform insights into strategic actions for success in your industry. https://www.delveinsight.com/case-study/immune-checkpoint-inhibitor-market-potential

Latest Report Offered By DelveInsight:

Ventricular Assist Devices Market https://www.delveinsight.com/report-store/ventricular-assist-devices-vad-market
Ventricular Assist Devices Market By Product Type (Left Ventricular Assist Devices, Right Ventricular Assist Devices, And Biventricular Assist Devices), By Application Type (Bridge-To-Transplant [Btt], Destination Therapy, And Others), By Design Type (Transcutaneous Ventricular Assist Devcies And Implantable Ventricular Assist Devices), By Type Of Flow (Pulsatile Flow And Continous Flow), By End User (Hospital And Clinics, Ambulatory Surgical Centers, And Others), by geography is expected to grow at a steady CAGR forecast till 2028 owing to the increasing prevalence of heart failure and cardiovascular diseases due to obesity, age, & unhealthy lifestyles and rising demand for organ transplants due to increasing prevalence of chronic ailments such as hypertension, diabetes, and others

B-cell Non-hodgkin Lymphoma Market https://www.delveinsight.com/report-store/b-cell-non-hodgkin-lymphoma-market
DelveInsight's "B-Cell Non-Hodgkin Lymphoma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the B-Cell Non-Hodgkin Lymphoma, historical and forecasted epidemiology as well as the B-Cell Non-Hodgkin Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Systemic Sclerosis Market
https://www.delveinsight.com/report-store/systemic-sclerosis-market
DelveInsight's "Systemic Sclerosis Market Insights, Epidemiology, and Market Forecast - 2032" comprehensively analyzes Systemic Sclerosis. The report includes a detailed examination of the historical and projected epidemiology data that includes diagnosed prevalent cases of Systemic Sclerosis segmented by gender-specific, age-specific, and type-specific cases.

Resorbable Vascular Scaffold Market
https://www.delveinsight.com/report-store/resorbable-vascular-scaffolds-market
"DelveInsight's 'Resorbable Vascular Scaffolds Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Resorbable Vascular Scaffolds and the historical and forecasted Resorbable Vascular Scaffolds market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vascular Stents Market
https://www.delveinsight.com/report-store/vascular-stents-market
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2028 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Nyxol (Phentolamine Mesylate) by Ocuphire Pharma expected to drive market size of Glaucoma here

News-ID: 3422284 • Views:

More Releases from DelveInsight Business Research

Spinocerebellar Ataxias Pipeline 2025: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights by DelveInsight
Spinocerebellar Ataxias Pipeline 2025: Comprehensive Clinical Trials and Therapi …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Spinocerebellar Ataxias pipeline constitutes 8+ key companies continuously working towards developing 10+ Spinocerebellar Ataxias treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Spinocerebellar Ataxias Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Spinocerebellar Ataxias Market. The Spinocerebellar
Presbyopia Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Observes
Presbyopia Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight O …
The Presbyopia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Presbyopia pipeline products will significantly revolutionize the Presbyopia market dynamics. DelveInsight's "Presbyopia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Presbyopia, historical and forecasted epidemiology as well as the Presbyopia market trends in the United States, EU5 (Germany, Spain, Italy, France,
Idiopathic Pulmonary Fibrosis Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates
Idiopathic Pulmonary Fibrosis Market Insights Highlight Expanding Outlook Till 2 …
DelveInsight's "Idiopathic Pulmonary Fibrosis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Idiopathic Pulmonary Fibrosis, historical and forecasted epidemiology as well as the Idiopathic Pulmonary Fibrosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. The latest healthcare forecast report provides an in-depth analysis of Idiopathic Pulmonary Fibrosis, offering comprehensive insights into the Idiopathic Pulmonary Fibrosis revenue trends,
Myocardial Infarction Market Positioned for Accelerated Development Through 2034, DelveInsight Finds
Myocardial Infarction Market Positioned for Accelerated Development Through 2034 …
DelveInsight's "Myocardial Infarction Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myocardial Infarction, historical and forecasted epidemiology as well as the Myocardial Infarction market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Myocardial Infarction market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Myocardial Infarction Market Forecast https://www.delveinsight.com/sample-request/myocardial-infarction-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the

All 5 Releases


More Releases for Nyxol

Presbyopia Pipeline Analysis, Clinical Trials, EMA, PDMA, FDA Approvals, Medicat …
(Albany, USA) DelveInsight's, "Presbyopia Pipeline Insight" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Presbyopia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Presbyopia Pipeline. Dive
Night Vision Disturbance Therapeutics Market Size is expected to grow by 2034, e …
DelveInsight's "Night Vision Disturbance Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Night Vision Disturbance (NVD), historical and forecasted epidemiology as well as the Night Vision Disturbance (NVD) market trends in the United States, EU4 and the UK (Germany, France, Italy, Spain) and the United Kingdom, and Japan. Discover Key Insights into the Night Vision Disturbance Market with DelveInsight's In-Depth Report @ Night
Night Vision Disturbance Market Size was highest in the US among the 7MM, accoun …
DelveInsight's "Night Vision Disturbance Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Night Vision Disturbance (NVD), historical and forecasted epidemiology as well as the Night Vision Disturbance (NVD) market trends in the United States, EU4 and the UK (Germany, France, Italy, Spain) and the United Kingdom, and Japan. Discover Key Insights into the Night Vision Disturbance Market with DelveInsight's In-Depth Report @ Night Vision
Presbyopia Market on Track for Major Expansion by 2034, According to DelveInsigh …
The Key Presbyopia Companies in the market include - Ocuphire Pharma, Inc., Novartis, Orasis Pharmaceuticals, Allergan, AbbVie, Orasis Pharmaceuticals, LENZ Therapeutics, Eyenovia, Orasis Pharmaceutical, Ocuphire Pharma, Novartis, Visus Therapeutics, and others. The Presbyopia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Presbyopia pipeline products will significantly revolutionize the Presbyopia market dynamics. DelveInsight's "Presbyopia Market Insights, Epidemiology, and Market Forecast-2034
Presbyopia Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Presbyopia pipeline constitutes 12+ key companies continuously working towards developing 12+ Presbyopia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Presbyopia Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Presbyopia Market. The Presbyopia Pipeline report embraces in-depth
Ocuphire Pharma "Nyxol + Pilocarpine" Market size expansion of Several Folds by …
[Las Vegas, United States] DelveInsight, a leader in healthcare research firm, has recently published an in-depth report on Nyxol + Pilocarpine (Ocuphire Pharma) providing insights into the drug market landscape and market forecast of Nyxol + Pilocarpine upto 2032. The report, titled "Nyxol + Pilocarpine Market Size, Forecast, and Emerging Insight - 2032" is now available for review and analysis. Are you interested in finding out the projected market size